Effect of chronic and selective endothelin receptor antagonism on microvascular function in Type 2 diabetes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 6, 2008, Pages

  Sachidanandam, Kamakshi ^a   Elgebaly, Mostafa M ^a   Harris, Alex K ^b   Hutchinson, Jim R ^b   Mezzetti, Erin M ^b   Portik Dobos, Vera ^b   Ergul, Adviye ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Goto Kakizaki rats; Microvessel; Vascular dysfunction

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ACETYLCHOLINE; ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; NITRIC OXIDE; CARDIOVASCULAR AGENT; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; PYRROLIDINE DERIVATIVE; SARAFOTOXINS S6; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VIPER VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; GOTO KAKIZAKI RAT; MALE; MESENTERIC ARTERY; MESENTERY BLOOD FLOW; MYOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION; VASODILATATION; ANIMAL; DIABETIC ANGIOPATHY; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MICROCIRCULATION; PATHOPHYSIOLOGY; UPREGULATION; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; CARDIOVASCULAR AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; MALE; MESENTERIC ARTERIES; MICROCIRCULATION; MYOGRAPHY; PEPTIDES, CYCLIC; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; UP-REGULATION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS; VIPER VENOMS;

EID: 49249107669     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.91487.2007     Document Type: Article

References (37)

1. American Diabetes Association. National Diabetes Fact Sheet. Alexandria, VA: ADA, 2007, http://www.diabetes.org/diabetes-statistics.jsp.
2. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110: 2233-2240, 2004.
3. Brondum E, Nilsson H, Aalkjaer C. Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models. Horm Metab Res 37, Suppl 1: 56-60, 2005.
4. B receptor antagonism on oxidative stress in type 2 diabetes. Vascul Pharmacol 47: 125-130, 2007.
5. Gregan B, Jurgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, Rosenthal W, Oksche A. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 279: 27679-27687, 2004.
6. Gregan B, Schaefer M, Rosenthal W, Oksche A. Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers. J Cardiovasc Pharmacol 44: S30-S33, 2004.
7. B receptor heterodimer. Cell Mol Neurobiol 22: 207-226, 2002.
8. Harris AK, Hutchinson JR, Sachidanandam K, Johnson MH, Dorrance AM, Stepp DW, Fagan SC, Ergul A. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes 54: 2638-2644, 2005.
9. B receptors for endothelin induces hypertension in the hamster. Am J Physiol Heart Circ Physiol 289: H1258-H1264, 2005.
10. Honore JC, Fecteau MH, Wessale JL, D'Orleans-Juste P. Effects of selective and non-selective endothelin receptor blockade on ET-1-induced pressor response in the hamster. J Cardiovasc Pharmacol 44: S68-S71, 2004.
11. Honore JC, Proteau C, D'Orleans-Juste P. Endothelin B receptors located on the endothelium provide cardiovascular protection in the hamster. Clin Sci (Lond) 103, Suppl 48: 280S-283S, 2002.
12. Ibrahim J, Berk BC, Hughes AD. Comparison of simultaneous measurements of blood pressure by tail-cuff and carotid arterial methods in conscious spontaneously hypertensive and Wistar-Kyoto rats. Clin Exp Hypertens 28: 57-72, 2006.
13. Jonk AM, Houben AJ, de Jongh RT, Serne EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology 22: 252-260, 2007.
14. Katakam PV, Pollock JS, Pollock DM, Ujhelyi MR, Miller AW. Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistant rats. Am J Physiol Heart Circ Physiol 280: H522-H527, 2001.
15. i signaling. Am J Physiol Regul Integr Comp Physiol 290: R145-R153, 2006.
16. Katakam PV, Ujhelyi MR, Miller AW. EDHF-mediated relaxation is impaired in fructose-fed rats. J Cardiovasc Pharmacol 34: 461-467, 1999.
17. Makino A, Kamata K. Effects of chronic administration of L-arginine on vasoactive responses induced by endothelin-1 and its plasma level in streptozotocin-induced diabetic rats. J Smooth Muscle Res 38: 101-115, 2002.
18. Makino A, Kamata K. Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br J Pharmacol 123: 1065-1072, 1998.
19. 2 of vasoconstriction induced by an alpha-agonist in mesenteric arterial bed from diabetic rats. Diabetologia 41: 1410-1418, 1998.
20. Makino A, Ohuchi K, Kamata K. Mechanisms underlying the attenuation of endothelium-dependent vasodilatation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat. Br J Pharmacol 130: 549-556, 2000.
21. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 53: 2060-2066, 2004.
22. Miller AW, Dimitropoulou C, Han G, White RE, Busija DW, Carrier GO. Epoxyeicosatrienoic acid-induced relaxation is impaired in insulin resistance. Am J Physiol Heart Circ Physiol 281: H1524-H1531, 2001.
23. Miller AW, Katakam PV, Lee HC, Tulbert CD, Busija DW, Weintraub NL. Arachidonic acid-induced vasodilation of rat small mesenteric arteries is lipoxygenase-dependent. J Pharmacol Exp Ther 304: 139-144, 2003.
24. Miller AW, Tulbert C, Puskar M, Busija DW. Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance. Hypertension 40: 78-82, 2002.
25. A-selective receptor antagonist. J Pharmacol Exp Ther 276: 473-481, 1996.
26. A receptor blockade in prediabetic NOD mice. J Cardiovasc Pharmacol 44: S105-S108, 2004.
27. Potenza MA, Marasciulo FL, Chieppa DM, Brigiani GS, Formoso G, Quon MJ, Montagnani M. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 289: H813-H822, 2005.
28. Sachidanandam K, Harris A, Hutchinson J, Ergul A. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Exp Biol Med (Maywood) 231: 1016-1021, 2006.
29. B receptors in resistance artery remodeling in diabetes. Diabetes 56: 2753-2758, 2007.
30. Sauvageau S, Thorin E, Caron A, Dupuis J. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 231: 840-846, 2006.
31. Serne EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 50: 204-211, 2007.
32. Taylor PD, Wickenden AD, Mirrlees DJ, Poston L. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat. Br J Pharmacol 111: 42-48, 1994.
33. Tooke JE. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications 14: 197-200, 2000.
34. Tooke JE, Goh KL. Vascular function in Type 2 diabetes mellitus and pre-diabetes: the case for intrinsic endotheliopathy. Diabet Med 16: 710-715, 1999.
35. Wessale JL, Adler AL, Novosad EI, Calzadilla SV, Dayton BD, Marsh KC, Winn M, Jae HS, von Geldern TW, Opgenorth TJ, Wu-Wong JR. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci (Lond) 103, Suppl 1: 112S-117S, 2002.
36. Whitesall SE, Hoff JB, Vollmer AP, D'Alecy LG. Comparison of simultaneous measurement of mouse systolic arterial blood pressure by radiotelemetry and tail-cuff methods. Am J Physiol Heart Circ Physiol 286: H2408-H2415, 2004.
37. Zuccarello M, Boccaletti R, Rapoport RM. Does blockade of endothelinB1-receptor activation increase endothelinB2/endothelinA receptormediated constriction in the rabbit basilar artery? J Cardiovasc Pharmacol 33: 679-684, 1999.